NDAORALSOLUTION
Approved
Jan 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
LYRICA (pregabalin) by Viatris (2) is 2 -delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. First approved in 2010.
Drug data last refreshed 5h ago · AI intelligence enriched 8h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LYRICA (pregabalin) is an oral small-molecule anticonvulsant that binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. It reduces calcium-dependent release of pro-nociceptive neurotransmitters in the spinal cord and modulates pain transmission through descending noradrenergic and serotonergic pathways. LYRICA is indicated for neuropathic pain, fibromyalgia, and post-herpetic neuralgia in patients seeking alternatives to opioid therapy.
$0.072BPart D
LOE ApproachingStable
Product approaching loss of exclusivity with modest Part D spending signals a contracting revenue base requiring focus on retention and lifecycle management initiatives.
Mechanism of Action
2 -delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. Although the mechanism of action of pregabalin has not been fully elucidated, results with genetically modified mice and with compounds structurally related to pregabalin (such as gabapentin)…
Indications
Worked on LYRICA at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.